{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:32:42Z","timestamp":1784161962076,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s13318-019-00564-w","type":"journal-article","created":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:14:53Z","timestamp":1559445293000},"page":"837-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of Life"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9758-8004","authenticated-orcid":false,"given":"Hirokazu","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Echizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/082585970602200202","volume":"22","author":"M Mirhosseini","year":"2006","unstructured":"Mirhosseini M, Oneschuk D, Hunter B, Hanson J, Quan H, Amigo P. The role of antibiotics in the management of infection-related symptoms in advanced cancer patients. J Palliat Care. 2006;22:69\u201374.","journal-title":"J Palliat Care"},{"key":"564_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11605-008-0505-z","volume":"12","author":"J Bachmann","year":"2008","unstructured":"Bachmann J, Heiligensetzer M, Krakowski-Roosen H, B\u00fcchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12:1193\u2013201. \n                    https:\/\/doi.org\/10.1007\/s11605-008-0505-z\n                    \n                  .","journal-title":"J Gastrointest Surg"},{"key":"564_CR4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/bmj.315.7117.1219","volume":"315","author":"E Bruera","year":"1997","unstructured":"Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. 1997;315:1219\u201322.","journal-title":"BMJ"},{"key":"564_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1128\/AAC.42.5.1303","volume":"42","author":"HA Kirst","year":"1998","unstructured":"Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42:1303\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"564_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1086\/491708","volume":"42","author":"RC Moellering Jr","year":"2006","unstructured":"Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3\u20134.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"564_CR7","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"DP Levine","year":"2006","unstructured":"Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl 1):S5\u201312.","journal-title":"Clin Infect Dis"},{"key":"564_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82\u201398. \n                    https:\/\/doi.org\/10.2146\/ajhp080434\n                    \n                  .","journal-title":"Am J Health Syst Pharm"},{"key":"564_CR9","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","volume":"49","author":"DS Buelga","year":"2005","unstructured":"Buelga DS, de Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, Garc\u00eda MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49:4934\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1078155209355847","volume":"16","author":"H Al-Kofide","year":"2010","unstructured":"Al-Kofide H, Zaghloul I, Al-Naim L. Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010;16:245\u201350. \n                    https:\/\/doi.org\/10.1177\/1078155209355847\n                    \n                  .","journal-title":"J Oncol Pharm Pract"},{"key":"564_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1248\/bpb.32.99","volume":"32","author":"S Omote","year":"2009","unstructured":"Omote S, Yano Y, Hashida T, Masuda S, Yano I, Katsura T, Inui K. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull. 2009;32:99\u2013104.","journal-title":"Biol Pharm Bull"},{"key":"564_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/CIA.S52259","volume":"8","author":"T Mizuno","year":"2013","unstructured":"Mizuno T, Mizokami F, Fukami K, Ito K, Shibasaki M, Nagamatsu T, Furuta K. The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2013;8:1323\u20138. \n                    https:\/\/doi.org\/10.2147\/CIA.S52259\n                    \n                  .","journal-title":"Clin Interv Aging"},{"key":"564_CR13","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","volume":"166","author":"LK Hidayat","year":"2006","unstructured":"Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138\u201344.","journal-title":"Arch Intern Med"},{"key":"564_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507\u201314. \n                    https:\/\/doi.org\/10.1086\/600884\n                    \n                  .","journal-title":"Clin Infect Dis"},{"key":"564_CR15","unstructured":"Common Terminology Criteria for Adverse Events, May 28, 2009. Available from: \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed 16 Dec 2017."},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF01086153","volume":"4","author":"RJ Sawchuk","year":"1976","unstructured":"Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183\u201395.","journal-title":"J Pharmacokinet Biopharm"},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","volume":"34","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009;34:473\u201383. \n                    https:\/\/doi.org\/10.1111\/j.1365-2710.2008.01016.x\n                    \n                  .","journal-title":"J Clin Pharm Ther"},{"key":"564_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000621","author":"H Nakayama","year":"2019","unstructured":"Nakayama H, Suzuki M, Usuki K, Kato T. Amikacin pharmacokinetics in terminal stage of hematological malignancy. Ther Drug Monit. 2019. \n                    https:\/\/doi.org\/10.1097\/ftd.0000000000000621\n                    \n                  .","journal-title":"Ther Drug Monit"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1089\/jpm.2015.0548","volume":"19","author":"AD Masman","year":"2016","unstructured":"Masman AD, Tibboel D, Baar FP, van Dijk M, Mathot RA, van Gelder T. Prevalence and implications of abnormal laboratory results in patients in the terminal phase of life. J Palliat Med. 2016;19:822\u20139. \n                    https:\/\/doi.org\/10.1089\/jpm.2015.0548\n                    \n                  .","journal-title":"J Palliat Med"},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcsm.12012","volume":"6","author":"K Cvan Trobec","year":"2015","unstructured":"Cvan Trobec K, Kerec Kos M, Trontelj J, Grabnar I, Tschirner A, Palus S, Anker SD, Springer J, Lainscak M. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle. 2015;6:45\u201352. \n                    https:\/\/doi.org\/10.1002\/jcsm.12012\n                    \n                  .","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"564_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40262-015-0345-4","volume":"55","author":"LG Franken","year":"2016","unstructured":"Franken LG, Masman AD, de Winter BC, Koch BC, Baar FP, Tibboel D, van Gelder T, Mathot RA. Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill adult patients. Clin Pharmacokinet. 2016;55:697\u2013709. \n                    https:\/\/doi.org\/10.1007\/s40262-015-0345-4\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","volume":"52","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975\u201381. \n                    https:\/\/doi.org\/10.1093\/cid\/cir124\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"564_CR23","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","volume":"42","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35\u20139.","journal-title":"Clin Infect Dis"},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","volume":"51","author":"A Marsot","year":"2012","unstructured":"Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51:1\u201313. \n                    https:\/\/doi.org\/10.2165\/11596390-000000000-00000\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"564_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jcph.782","volume":"57","author":"S Lanke","year":"2017","unstructured":"Lanke S, Yu T, Rower JE, Balch AH, Korgenski EK, Sherwin CM. AUC-guided vancomycin dosing in adolescent patients with suspected sepsis. J Clin Pharmacol. 2017;57:77\u201384. \n                    https:\/\/doi.org\/10.1002\/jcph.782\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"key":"564_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13318-018-0534-2","volume":"44","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Gao F, Chen C, Ma L, Yang T, Liu X, Liu Y, Wang X, Zhao X, Que C, Li S, Lv J, Cui Y, Yang L. Development of a population pharmacokinetic model of vancomycin and its application in Chinese geriatric patients with pulmonary infections. Eur J Drug Metab Pharmacokinet. 2019;44:361\u201370. \n                    https:\/\/doi.org\/10.1007\/s13318-018-0534-2\n                    \n                  .","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"564_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00007691-198907000-00013","volume":"11","author":"RD Pryka","year":"1989","unstructured":"Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Monit. 1989;11:450\u20134.","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00564-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:24:35Z","timestamp":1590881075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00564-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00564-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"1 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of the present study was approved by Ethics Committee of NTT Medical Center Tokyo prior to the study (the approval number: 17\u2012227).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The IRB waived the requirement of written informed consent from patients, because the present study had a retrospective design and the data used were obtained from routine medical care including TDM. Nevertheless, the study was conducted with full consideration of protecting patients\u2019 personal information according to the guidelines on privacy policy.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}